Sight Sciences, Inc.

SGHT ·Healthcare, Medical Devices, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-38.4M $-51.5M $-55.5M $-86.2M $-63.0M $-34.7M
Depreciation & Amortization $487.0K $712.0K $614.0K — — —
Depreciation $300.0K $500.0K $600.0K $710.0K $632.0K $554.0K
Amortization — — — — — —
Stock-Based Compensation $13.1M $17.1M $14.6M $13.0M $5.1M $497.0K
Net Cash from Operating Activities $-29.7M $-22.4M $-47.2M $-76.0M $-52.5M $-32.2M
Investing Activities
Capital Expenditures $224.0K $385.0K $791.0K $970.0K $813.0K $953.0K
Business Acquisitions — — — — — —
Net Cash from Investing Activities $-224.0K $-385.0K $-791.0K $-970.0K $-813.0K $-953.0K
Financing Activities
Dividends Paid — — — — — —
Stock Repurchases — — — — — —
Net Cash from Financing Activities $1.8M $5.0M $1.1M $1.2M $252.5M $73.4M
Net Change in Cash $-28.1M $-17.8M $-46.9M $-75.7M $199.2M $40.3M
Free Cash Flow $-29.9M $-22.7M $-48.0M $-76.9M $-53.4M $-33.1M